Novel bag proteins and nucleic acid molecules encoding them
AssigneeThe Burnham Institute
InventorsJOHN C. REED, SHINICHI TAKAYAMA
Life of this patent
Estimating the term…
Abstract
The present invention provides a family of BAG-1 related proteins from humans (BAG-1L, BAG-1, BAG-2, BAG-3, BAG-4 and BAG-5), the invertebrate C. elegans (BAG-1, BAG-2) and the fission yeast S. pombe (BAG-1A, BAG-1B) and the nucleic acid molecules that encode them.
Claims34
A compound of the formula,
- RN-R1X1R2X2R3X3R4X4R5X5R6X6R7X7X8R9X9R10X10R11X11-RC
- wherein,
- RN is a group of about 1 to 552 independently selected amino acids;
- R1 is a group of 3 independently selected amino acids;
- X1 is an amino acid with a charged or uncharged R group;
- R2 is a group of 7 independently selected amino acids;
- X2 is an amino acid with a charged R group;
- R3 is a group of 5 independently selected amino acids;
- X3 is an amino acid with an apolar R group;
- R4 is a group of 3 independently selected amino acids;
- X4 is an amino acid with charged R group;
- R5 is a single independently selected amino acid;
- X5 is an amino acid with apolar or uncharged R group;
- R6 is a group of 15 independently selected amino acids;
- X6 is an amino acid with a charged or uncharged R group;
- R7 is a group of 2 independently selected amino acids;
- X7 is an amino acid with a charged R group;
- X8 is an amino acid with a charged R group;
- R9 is a group of 2 independently selected amino acids;
- X9 is an amino acid with an apolar R group;
- R10 is a group of 3 independently selected amino acids;
- X10 is an amino acid with an uncharged R group;
- R11 is a group of 2 independently selected amino acids;
- X11 is an amino acid with an apolar R group;
- and
- RC is a group of about 1 to 100 independently selected amino acids.
A substantially purified nucleic acid molecule having a nucleotide sequence corresponding to or complementary to at least 20 nucleotides from a nucleotide sequence selected from the group consisting of (SEQ ID NO:1), (SEQ ID NO:3), (SEQ ID NO:5), (SEQ ID NO:7), (SEQ ID NO:9), (SEQ ID NO:19), (SEQ ID NO:21) and (SEQ ID NO:23).
A substantially purified nucleic acid molecule having the nucleotide sequence of (SEQ ID NO:3).
A substantially purified nucleic acid molecule having the nucleotide sequence of (SEQ ID NO:5).
A substantially purified nucleic acid molecule having the nucleotide sequence of (SEQ ID NO:7).
A substantially purified nucleic acid molecule having the nucleotide sequence of (SEQ ID NO:9).
A substantially purified nucleic acid molecule having the nucleotide sequence of (SEQ ID NO:19).
A substantially purified nucleic acid molecule having the nucleotide sequence of (SEQ ID NO:21).
A substantially purified nucleic acid molecule having the nucleotide sequence of (SEQ ID NO:23).
A substantially purified BAG family protein comprising of the amino acid sequence selected from the group consisting of (SEQ ID NO:2), (SEQ ID NO:4), (SEQ ID NO:6), (SEQ ID NO:8), (SEQ ID NO:10), (SEQ ID NO:20), (SEQ ID NO:22) and (SEQ ID NO:24) or a fragment, a derivative or a mimetic thereof.
A substantially purified protein corresponding to the amino acid sequence of 157 to 204 of (SEQ ID NO:2).
A substantially purified protein corresponding to the amino acid sequence of 272 to 319 of (SEQ ID NO:2).
A substantially purified protein corresponding to the amino acid sequence of 164 to 211 of (SEQ ID NO:4).
A substantially purified protein corresponding to the amino acid sequence of 418 to 510 of (SEQ ID NO:20).
A substantially purified protein corresponding to the amino acid sequence of 378 to 457 of (SEQ ID NO:22).
A substantially purified protein corresponding to the amino acid sequence of 6 to 97 of (SEQ ID NO:24).
A substantially purified protein corresponding to the amino acid sequence of 180 to 257 of (SEQ ID NO:24).
A substantially purified protein corresponding to the amino acid sequence of 272 to 349 of (SEQ ID NO:24).
A substantially purified protein corresponding to the amino acid sequence of 362 to 444 of (SEQ ID NO:24).
A pharmaceutical composition comprising a substantially purified BAG family protein comprising of the amino acid sequence selected from the group consisting of (SEQ ID NO:2), (SEQ ID NO:4), (SEQ ID NO:6), (SEQ ID NO:8), (SEQ ID NO:10), (SEQ ID NO:20), (SEQ ID NO:22) and (SEQ ID NO:24), or a fragment, a derivative or a mimetic thereof, useful for modulating tumor cell proliferation, cell migration and metastasis, and steroid hormone receptor function.
A method for detecting the presence of a first nucleic acid molecule that encodes a BAG family protein in a sample, comprising the steps of:
- a. obtaining the sample;
- b. adding to said sample a second nucleic acid molecule capable of hybridizing with said first nucleic acid molecule under suitable conditions for the binding of said second nucleic acid molecule with said first nucleic acid molecule;
- and
- c. detecting said hybridized first and second nucleic acid molecules.
A method of determining the risk of metastatic spread of cancer or prognosis of cancer patients by determining the level of expression of a BAG-family protein.
Dependencies are inferred from the claim text.